Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
67,949.47 +2,220.49 (+3.38%) CMC Crypto 200
1,375.38 +44.78 (+3.36%)
Atara Biotherapeutics, Inc. (ATRA)
After hours:
| Previous close | 9.76 |
| Open | 9.67 |
| Bid | 9.93 x 100 |
| Ask | 10.33 x 100 |
| Day's range | 9.67 - 10.18 |
| 52-week range | 4.97 - 63.38 |
| Volume | |
| Avg. volume | 83,173 |
| Market cap | 49.876M |
| Beta (5Y monthly) | 0.52 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -53.00 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 104.00 |
Business WireAtara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
THOUSAND OAKS, Calif., July 17, 2024--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for tabelecleucel (tab-cel®) indicated as monotherapy for treatment of adult and pediatric pa
GlobeNewswirePresenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 73rd Emerging Growth Conference on July 17 & 18 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companie
ZacksAll You Need to Know About Atara Biotherapeutics (ATRA) Rating Upgrade to Strong Buy
Atara Biotherapeutics (ATRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
